These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38224338)

  • 21. Cholinesterase inhibitors associated with lower rate of mortality in dementia patients with heart failure: a nationwide propensity weighting study.
    Hsieh MJ; Lee CH; Chen DY; Wu CL; Huang YT; Chang SH
    Clin Auton Res; 2023 Dec; 33(6):715-726. PubMed ID: 37935929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Association Between the Use of Cholinesterase Inhibitors and Cardiovascular Events Among Older Patients With Alzheimer Disease.
    Hsiao SH; Hwang TJ; Lin FJ; Sheu JJ; Wu CH
    Mayo Clin Proc; 2021 Feb; 96(2):350-362. PubMed ID: 33549256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study.
    Rege S; Carnahan RM; Johnson ML; Chen H; Holmes HM; Aparasu RR
    Drugs Aging; 2021 Jun; 38(6):493-502. PubMed ID: 33763822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.
    Gardette V; Andrieu S; Lapeyre-Mestre M; Coley N; Cantet C; Ousset PJ; Grand A; Monstastruc JL; Vellas B
    CNS Drugs; 2010 May; 24(5):431-42. PubMed ID: 20369907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
    Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
    J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials.
    Truong C; Recto C; Lafont C; Canoui-Poitrine F; Belmin JB; Lafuente-Lafuente C
    Neurology; 2022 Nov; 99(20):e2313-e2325. PubMed ID: 36096687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
    Kennedy RE; Cutter GR; Fowler ME; Schneider LS
    JAMA Netw Open; 2018 Nov; 1(7):e184080. PubMed ID: 30646339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
    Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
    Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors.
    Talwar A; Chatterjee S; Sherer J; Abughosh S; Johnson M; Aparasu RR
    Drugs Aging; 2024 Apr; 41(4):339-355. PubMed ID: 38467994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
    Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
    J Am Geriatr Soc; 2022 Mar; 70(3):820-830. PubMed ID: 34854475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer's Disease.
    Linna M; Vuoti S; Silander K; Hörhammer I; Halminen O; Mikkola T; Koivuranta-Vaara P; Virta LJ; Koivusalo M; Ylisaukko-Oja T
    J Alzheimers Dis; 2019; 71(4):1297-1308. PubMed ID: 31524158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of rivastigmine in Alzheimer's disease.
    Nguyen K; Hoffman H; Chakkamparambil B; Grossberg GT
    Neurodegener Dis Manag; 2021 Feb; 11(1):35-48. PubMed ID: 33198569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
    Kröger E; van Marum R; Souverein P; Egberts T
    Drugs Aging; 2010 Aug; 27(8):663-75. PubMed ID: 20658794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
    Jasiecki J; Wasąg B
    Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study.
    Canevelli M; Adali N; Kelaiditi E; Cantet C; Ousset PJ; Cesari M;
    Phytomedicine; 2014 May; 21(6):888-92. PubMed ID: 24548724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
    Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
    Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study.
    Stephenson A; Seitz DP; Fischer HD; Gruneir A; Bell CM; Gershon AS; Fu L; Anderson GM; Austin PC; Rochon PA; Gill SS
    Drugs Aging; 2012 Mar; 29(3):213-223. PubMed ID: 22332932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
    Haake A; Nguyen K; Friedman L; Chakkamparambil B; Grossberg GT
    Expert Opin Drug Saf; 2020 Feb; 19(2):147-157. PubMed ID: 31976781
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.